SCHEMBL4522191

SCHEMBL4522191

CC(C)Oc1ccccc1N1CCN(CC(O)CN2C(=O)C3CC=CCC3C2=O)CC1

nearest known ligand 0.54

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
ADRA1A P35348 11/20 0.54
ADRA1D P25100 10/20 0.54
ADRA1B P35368 5/20 0.54
HTR1A P08908 4/20 0.52
DRD2 P14416 3/20 0.52
HTR7 P34969 3/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4527648 0.99 ADRA1D (0.53) ADRA1AADRA1DADRA1BHTR1ADRD2
SCHEMBL4528834 0.90 ADRA1A (0.54) ADRA1AADRA1DADRA1BHTR1ADRD2
SCHEMBL4522028 0.90 ADRA1A (0.56) ADRA1AADRA1DADRA1BHTR1ADRD2
SCHEMBL6213851 0.90 HTR1A (0.64) ADRA1BHTR1ADRD2HTR7
Hydrochloric Acid SCHEMBL4527136 0.89 ADRA1A (0.55) ADRA1AADRA1DADRA1BHTR1ADRD2
Hydrochloric Acid SCHEMBL6408516 0.89 HTR1A (0.63) HTR1ADRD2HTR7
SCHEMBL4533380 0.89 ADRA1A (0.49) ADRA1AADRA1DADRA1BHTR1A
SCHEMBL5807739 0.88 ADRA1A (0.52) ADRA1AADRA1DADRA1BHTR1ADRD2
Hydrochloric Acid SCHEMBL4521926 0.88 ADRA1A (0.48) ADRA1AADRA1DADRA1BHTR1A
Hydrochloric Acid SCHEMBL6210504 0.87 HTR1A (0.61) ADRA1BHTR1ADRD2HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006092710-A1 METABOLITES OF 2-{3-[4-(2-ISOPROPOXYPHENYL) PIPERAZIN-1-YL]-PROPYL}-3A,4,7,7A-TETRAHYDRO-1H-ISOINDOLE-1,3-(2H)-DIONE RANBAXY LABORATORIES LIMITED (IN) 2006-09-08 WO claimed
US-20090312344-A1 ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2009-12-17 US disclosed
EP-1758583-A2 ARYLPIPERAZINE DERIVATIVES USEFUL AS ADRENERGIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2007-03-07 EP disclosed
WO-2006092710-A1 METABOLITES OF 2-{3-[4-(2-ISOPROPOXYPHENYL) PIPERAZIN-1-YL]-PROPYL}-3A,4,7,7A-TETRAHYDRO-1H-ISOINDOLE-1,3-(2H)-DIONE RANBAXY LABORATORIES LIMITED (IN) 2006-09-08 WO disclosed
WO-2005118537-A2 ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2005-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312344-A1 ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS ADRA1D, ADRB1, ADRA1A ADRA1A 3/4885ADRA1D 1/4885ADRA1B 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.